Rhythm Pharmaceuticals, Inc. RYTM Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s investment proceeds?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported investment proceeds of $99.25M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s investment proceeds changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s investment proceeds increased by 70.1% year-over-year, from $58.33M to $99.25M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s investment proceeds?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s investment proceeds has grown at a -8.6% compound annual growth rate (CAGR), from $361.25M to $252.47M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.